Skip to main
CLLS
CLLS logo

Cellectis SA (CLLS) Stock Forecast & Price Target

Cellectis SA (CLLS) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 8%

Bulls say

Cellectis SA is making significant strides in the biotechnology sector, particularly with its proprietary gene-editing technologies, which position the company favorably within the competitive landscape of immuno-oncology. The company’s robust portfolio of allogeneic UCART product candidates and gene-edited HSPC candidates highlights its commitment to innovative therapeutic solutions, potentially resulting in expansive market opportunities. Furthermore, Cellectis's advancements in clinical trial progress and collaborations with leading industry partners underscore its strong growth prospects, enhancing investor confidence in the company's long-term value.

Bears say

Cellectis SA's reliance on clinical-stage development carries inherent risks, particularly reflected in the delayed timelines for its UCART product candidates, which may hinder potential revenue streams and investor confidence. Additionally, the company’s increasing operational costs and R&D expenditures, without corresponding advancements in monetizable products, contribute to a concerning financial outlook. Furthermore, the competitive landscape in the gene-editing and immuno-oncology sectors poses significant challenges, as Cellectis must navigate scientific and regulatory hurdles to achieve commercial viability.

Cellectis SA (CLLS) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cellectis SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cellectis SA (CLLS) Forecast

Analysts have given Cellectis SA (CLLS) a Buy based on their latest research and market trends.

According to 12 analysts, Cellectis SA (CLLS) has a Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cellectis SA (CLLS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.